197 related articles for article (PubMed ID: 32065713)
1. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
Schwarze-Zander C; Piduhn H; Boesecke C; Schlabe S; Stoffel-Wagner B; Wasmuth JC; Strassburg CP; Rockstroh JK
HIV Med; 2020 Jul; 21(6):378-385. PubMed ID: 32065713
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
Tabak F; Zerdali E; Altuntaş O; Gunduz A; Bolukcu S; Mete B; Nakir IY; Kumbasar Karaosmanoglu H; Yildiz DS; Meric Koc M; Dokmetas İ;
Int J STD AIDS; 2021 May; 32(6):562-569. PubMed ID: 33599173
[TBL] [Abstract][Full Text] [Related]
3. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Suzuki K; Suda G; Yamamoto Y; Abiko S; Kinoshita K; Miyamoto S; Sugiura R; Kimura M; Maehara O; Yamada R; Kitagataya T; Shigesawa T; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
PLoS One; 2022; 17(1):e0261760. PubMed ID: 35051189
[TBL] [Abstract][Full Text] [Related]
5. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
Kauppinen KJ; Kivelä P; Sutinen J
AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
[TBL] [Abstract][Full Text] [Related]
6. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
Milinkovic A; Berger F; Arenas-Pinto A; Mauss S
AIDS; 2019 Dec; 33(15):2387-2391. PubMed ID: 31764103
[TBL] [Abstract][Full Text] [Related]
7. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Kauppinen KJ; Aho I; Sutinen J
AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
[TBL] [Abstract][Full Text] [Related]
8. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Ikeda M; Wakabayashi Y; Okamoto K; Yanagimoto S; Okugawa S; Moriya K
AIDS Res Ther; 2021 May; 18(1):30. PubMed ID: 34044856
[TBL] [Abstract][Full Text] [Related]
9. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
10. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
[TBL] [Abstract][Full Text] [Related]
11. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile.
Squillace N; Ricci E; Menzaghi B; De Socio GV; Passerini S; Martinelli C; Mameli MS; Maggi P; Falasca K; Cordier L; Celesia BM; Salomoni E; Di Biagio A; Pellicanò GF; Bonfanti P;
Drug Des Devel Ther; 2020; 14():5515-5520. PubMed ID: 33364747
[TBL] [Abstract][Full Text] [Related]
13. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
[TBL] [Abstract][Full Text] [Related]
14. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
[TBL] [Abstract][Full Text] [Related]
15. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
16. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
[TBL] [Abstract][Full Text] [Related]
17. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Toyoda H; Leong J; Landis C; Atsukawa M; Watanabe T; Huang DQ; Liu J; Quek SXZ; Ishikawa T; Arai T; Yokohama K; Chuma M; Takaguchi K; Uojima H; Senoo T; Dang H; Maeda M; Hoang J; Le RH; Yasuda S; Thin KN; Tran S; Chien N; Henry L; Asai A; Fukunishi S; Cheung R; Lim SG; Trinh HN; Nguyen MH
Hepatology; 2021 Aug; 74(2):656-666. PubMed ID: 33706421
[TBL] [Abstract][Full Text] [Related]
18. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
19. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
[TBL] [Abstract][Full Text] [Related]
20. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]